Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Chinese origin

• diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis

Exclusion Criteria:

• Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms

• HIV (human immunodeficiency virus) infections

• Hepatitis A

• Syphilis

• immunodeficiency

• rheumatic disease or Sjogren syndrome

• heart disease

• severe depression

• pregnancy or lactation

• conditions interfering with Magnetic Resonance Imaging (MRI)

• Gadolinium DTPA (Gadovist, contrast agent) allergy

• allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance

• participation in other trial